



Correction to: Prolonged stable disease in a uveal melanoma patient with germline *MBD4* nonsense mutation treated with pembrolizumab and ipilimumab

Peter A. Johansson¹  · Andrew Stark² · Jane M. Palmer¹ · Kieron Bigby^{3,4,5} · Kelly Brooks¹ · Olivia Rolfe² · Antonia L. Pritchard^{1,6} · Kevin Whitehead⁷ · Sunil Warriar² · William Glasson² · Nicholas K. Hayward¹

Published online: 30 May 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Correction to: Immunogenetics (2019) 71:433–436
<https://doi.org/10.1007/s00251-019-01108-x>

The authors regret that the online version of this article contains an error. The *MBD4* mutation in sample MM138 was given an incorrect dbSNP ID. The correct ID is rs769076971.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1007/s00251-019-01108-x>

✉ Peter A. Johansson
peter.johansson@qimrberghofer.edu.au

¹ QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia

² Queensland Ocular Oncology Service, The Terrace Eye Centre, Brisbane, QLD, Australia

³ Montserrat Cancer Care, North Lakes Day Hospital, North Lakes, QLD, Australia

⁴ Redcliffe Hospital, Anzac Ave, Redcliffe, QLD, Australia

⁵ School of Medicine, University of Queensland, St Lucia, QLD, Australia

⁶ The University of the Highlands and Islands, Inverness, UK

⁷ Sullivan Nicolaidis Pathology, Brisbane, QLD, Australia